QGEN

QIAGEN N.V. [QGEN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

QGEN Stock Summary

QGEN has more than 10 years of cash runway (128 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

QGEN

Top 10 Correlated Stocks

QGEN

In the News

QGEN Financial details

Company Rating

Strong Buy

Market Cap

8.89B

Income

341.3M

Revenue

1.97B

Book val./share

17.2

Cash/share

4.78

Dividend

1.32

Dividend %

3.21%

Employees

5.19K

Optionable

Shortable

Yes

Earnings

29 Apr 2024

P/E

26.71

Forward P/E

PEG

-13.5

P/S

4.64

P/B

2.39

P/C

8.24

P/FCF

30.72

Quick Ratio

1.46

Current Ratio

1.99

Debt / Equity

0.4

LT Debt / Equity

0.24

EPS (TTM)

1.54

EPS next Y

EPS next Q

EPS this Y

-19.79%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

5.18%

Revenue Q/Q

6.99%

EPS Q/Q

25.71%

SMA20

-9.09%

SMA50

-9.09%

SMA100

Inst Own

45.17%

Inst Trans

0.79%

ROA

ROE

ROC

0.09%

Gross Margin

64%

Oper. Margin

24%

Profit Margin

17%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

34.74-47.7

52W High

-16.23%

52W Low

+15.79%

RSI

Rel Volume

0.57

Avg Volume

1.13M

Volume

645.88K

Perf Week

-4.4%

Perf Month

-11.59%

Perf Quarter

7.01%

Perf Half Y

0.56%

Beta

0.419

Volatility

0.66%, 1.79%

Prev Close

0.36%

Price

39.37

Change

-0.43%

QGEN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	6.94	8.44	10.18	9.7	8.88
Net income per share	-0.19	0.33	2.32	1.92	1.54
Operating cash flow per share	1.5	2.22	2.89	3.24	2.08
Free cash flow per share	0.25	0.85	1.96	2.56	1.34
Cash per share	3.42	3.22	4.82	6.42	4.78
Book value per share	11.53	11.21	14	15.7	17.21
Tangible book value per share	-1.07	-3.56	0.54	2.58	3.64
Share holders equity per share	11.53	11.21	14	15.7	17.21
Interest debt per share	8.09	9.48	9.03	8.7	7.16
Market cap	7.44B	11.71B	12.29B	11.01B	9.91B
Enterprise value	8.52B	13.14B	13.35B	12.14B	10.85B
P/E ratio	-179.35	159.02	23.98	26.01	29.03
Price to sales ratio	4.87	6.26	5.46	5.14	5.04
POCF ratio	22.47	23.79	19.23	15.39	21.56
PFCF ratio	132.87	62.28	28.42	19.45	33.4
P/B Ratio	2.93	4.72	3.97	3.18	2.6
PTB ratio	2.93	4.72	3.97	3.18	2.6
EV to sales	5.58	7.03	5.93	5.67	5.52
Enterprise value over EBITDA	15	17.18	14.47	14.73	16.68
EV to operating cash flow	25.75	26.69	20.9	16.97	23.62
EV to free cash flow	152.22	69.88	30.87	21.45	36.58
Earnings yield	-0.01	0.01	0.04	0.04	0.03
Free cash flow yield	0.01	0.02	0.04	0.05	0.03
Debt to equity	0.67	0.82	0.63	0.54	0.4
Debt to assets	0.33	0.34	0.32	0.3	0.25
Net debt to EBITDA	1.91	1.87	1.15	1.37	1.45
Current ratio	1.65	2.67	1.39	2.46	1.99
Interest coverage	4.53	7.6	11.57	9.11	8.34
Income quality	-7.98	6.68	1.25	1.69	1.35
Dividend Yield	0	0.05	0	0	0
Payout ratio	0	8.45	0	0.06	0
Sales general and administrative to revenue	0.07	0.06	0.06	0.06	0.06
Research and developement to revenue	0.1	0.07	0.08	0.09	0.1
Intangibles to total assets	0.53	0.55	0.48	0.46	0.49
Capex to operating cash flow	-0.83	-0.62	-0.32	-0.21	-0.35
Capex to revenue	-0.18	-0.16	-0.09	-0.07	-0.08
Capex to depreciation	-1.19	-1.45	-0.96	-0.72	-0.79
Stock based compensation to revenue	0.04	0.02	0.02	0.02	0.02
Graham number	6.99	9.15	27.02	26.03	24.43
ROIC	0.04	0.06	0.1	0.08	0.07
Return on tangible assets	-0.02	0.03	0.16	0.12	0.11
Graham Net	-7	-10.37	-7.01	-4.44	-3
Working capital	618.9M	1.03B	592.13M	1.42B	1.07B
Tangible asset value	-236.35M	-789.66M	118.35M	569.25M	805.21M
Net current asset value	-1.13B	-1.85B	-940.8M	-427.17M	-159.87M
Invested capital	0.67	0.82	0.63	0.54	0.4
Average receivables	406.89M	433.55M	400.99M	342.94M	419.7M
Average payables	77.09M	101.46M	109.69M	99.98M	91.44M
Average inventory	166.81M	230.94M	309.35M	342.74M	378.17M
Days sales outstanding	102.16	85.84	58.7	55.18	95.77
Days payables outstanding	59.37	67.12	46.14	47.61	41.38
Days of inventory on hand	119.55	165.41	149.28	172.61	195.87
Receivables turnover	3.57	4.25	6.22	6.61	3.81
Payables turnover	6.15	5.44	7.91	7.67	8.82
Inventory turnover	3.05	2.21	2.45	2.11	1.86
ROE	-0.02	0.03	0.17	0.12	0.09
Capex per share	-1.25	-1.37	-0.93	-0.68	-0.74

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.25	2.2	2.24	2.15	2.3
Net income per share	0.4	0.38	0.37	0.35	0.44
Operating cash flow per share	0.56	0.33	0.5	0.56	0.68
Free cash flow per share	0.35	0.15	0.36	0.38	0.45
Cash per share	6.42	5.82	6.02	4.59	4.78
Book value per share	15.69	16.11	16.37	16.68	17.2
Tangible book value per share	2.58	2.36	2.7	3.24	3.64
Share holders equity per share	15.69	16.11	16.37	16.68	17.2
Interest debt per share	8.49	8.57	8.59	6.76	6.98
Market cap	11.02B	10.15B	9.97B	8.97B	9.91B
Enterprise value	12.15B	11.67B	11.24B	9.87B	10.86B
P/E ratio	31	29.85	30.84	28.81	25.37
Price to sales ratio	22.12	20.92	20.14	18.84	19.47
POCF ratio	88.61	141.16	89.4	71.92	65.48
PFCF ratio	141.72	302.93	124.03	107.21	99.98
P/B Ratio	3.18	2.85	2.75	2.43	2.6
PTB ratio	3.18	2.85	2.75	2.43	2.6
EV to sales	24.39	24.05	22.72	20.74	21.32
Enterprise value over EBITDA	90.15	64.46	64.05	56.91	58.34
EV to operating cash flow	97.7	162.3	100.87	79.16	71.71
EV to free cash flow	156.27	348.3	139.94	118.01	109.49
Earnings yield	0.01	0.01	0.01	0.01	0.01
Free cash flow yield	0.01	0	0.01	0.01	0.01
Debt to equity	0.54	0.53	0.52	0.4	0.4
Debt to assets	0.3	0.3	0.3	0.25	0.25
Net debt to EBITDA	8.39	8.4	7.28	5.21	5.07
Current ratio	2.46	2.53	2.36	3.74	1.99
Interest coverage	7.03	8.93	7.81	7.47	10.81
Income quality	1.4	0.85	1.38	1.6	1.55
Dividend Yield	0	0	0	0	0
Payout ratio	0.01	0	0	0	0
Sales general and administrative to revenue	0.06	0.07	0.06	0.06	0.06
Research and developement to revenue	0.09	0.11	0.1	0.1	0.09
Intangibles to total assets	0.46	0.48	0.48	0.5	0.49
Capex to operating cash flow	-0.37	-0.53	-0.28	-0.33	-0.35
Capex to revenue	-0.09	-0.08	-0.06	-0.09	-0.1
Capex to depreciation	-0.85	-0.74	-0.61	-0.81	-1.01
Stock based compensation to revenue	0.03	0.03	0.02	0.03	0.02
Graham number	11.92	11.81	11.6	11.49	13.07
ROIC	0.02	0.02	0.02	0.01	0.02
Return on tangible assets	0.03	0.03	0.02	0.03	0.03
Graham Net	-4.44	-4.53	-4.34	-3.4	-3
Working capital	1.42B	1.36B	1.33B	1.44B	1.07B
Tangible asset value	569.25M	522.07M	596.88M	716.63M	805.21M
Net current asset value	-427.17M	-466.46M	-412.23M	-250.61M	-159.87M
Invested capital	0.54	0.53	0.52	0.4	0.4
Average receivables	317.36M	320.5M	314.92M	319.64M	421.17M
Average payables	90.79M	91.56M	84.16M	80.41M	80.52M
Average inventory	340.72M	369.39M	386.41M	395.6M	398.8M
Days sales outstanding	58.51	58.82	56.85	61.78	91.15
Days payables outstanding	49.24	42.69	41.35	38.89	46.18
Days of inventory on hand	178.52	192.64	193.09	201.92	218.6
Receivables turnover	1.54	1.53	1.58	1.46	0.99
Payables turnover	1.83	2.11	2.18	2.31	1.95
Inventory turnover	0.5	0.47	0.47	0.45	0.41
ROE	0.03	0.02	0.02	0.02	0.03
Capex per share	-0.21	-0.17	-0.14	-0.19	-0.24

QGEN Dividend History

QGEN Frequently Asked Questions

What is QIAGEN N.V. stock symbol ?

QIAGEN N.V. is a NL stock and trading under the symbol QGEN

What is QIAGEN N.V. stock quote today ?

QIAGEN N.V. stock price is $39.37 today.

Is QIAGEN N.V. stock public?

Yes, QIAGEN N.V. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.13M
Market Capitalization 8.89B
Employee 5.19K
CEO Mr. Thierry Bernard
Headquarters Venlo,NL
IPO Date 1996-06-28
Website https://www.qiagen.com

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.